University of California

University of Colorado

Other

Csl Behring Lengnau Ag

Annexon, Inc.

Anderson, Marc, O.

Alan S Verkman

Arnon Rosenthal

Michael W Leviten

Onur Cil

Marc Harris Levin

Sujin Lee

Mark J Kurth

Gregory P Owens

R Kiplin Guy

Rolf Spirig

Peter M Haggie

Tonghui Ma

Luis J V Galietta

Nitin Dattatraya Sonawane

Chatchai Muanprasat

David S Snyder

Nicoletta Pedemonte

Marc O Anderson

John Knapp

Sujatha Jayaraman

Joachim Biwersi

Byung-Ju Jin

Prashant A Padmawar

Lukmanee Tradtrantip

Puay-Wah Phuan

Wan Namkung

Ricardo De La Fuente Gonzalez

Jeffrey L Bennett

Cristina Esteva-Font

Puay Wah Phuan

Jeffery L Bennett

Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

CFTR regulators and methods of use thereof

The disclosure is directed to methods of treating tyrosine kinase inhibitor-induced diarrhea by administering a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination thereof.

Methods of treating tyrosine kinase inhibitor-induced diarrhea

Provided herein are inhibitors of SLC26A3, which is an anion (Cl, HCO, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), constipation-predominant irritable bowel syndrome (IBS-C), cystic fibrosis-associated constipation, meconium ileus, distal intestinal obstruction syndrome, calcium oxalate kidney stone disease, enteric hyperoxaluria and primary hyperoxalurias.

SLC26A3 inhibitors and use thereof

Provided herein are methods and systems for screening a candidate agent to determine whether the candidate agent modulates an activity of cultured cells. Compositions for screening a candidate agent are also provided herein.

Methods for high-content drug screening

The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.

Ocular pharmaceutical compositions

Provided herein are inhibitors of SLC26A3, which is an anion (CV, HCO, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), constipation-predominant irritable bowel syndrome (IBS-C), cystic fibrosis-associated constipation, meconium ileus, distal intestinal obstruction syndrome, calcium oxalate kidney stone disease, enteric hyperoxaluria and primary hyperoxalurias.

The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.

Compositions and methods for the treatment of neuromyelitis optica

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca-activated CI&#x2033; channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders or other diseases and disorders.

Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.

Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Provided herein are compounds that are urea transporter-A inhibitors that are useful for producing a strong diuretic response and may be used for treating refractory edema associated with cardiovascular, renal, and metabolic diseases, disorders, and conditions.

Small-molecule UT-A-selective urea transport inhibitors

Provided herein are small molecule inhibitors of pendrin. More specifically, the small molecules disclosed herein may be used to inhibit pendrin-mediated anion exchange. These small molecules may be used for treatment of diseases and disorders that are treatable by inhibiting pendrin, such as cystic fibrosis, rhinitis, chronic rhinosinusitis, exposure to an industrial toxin, certain viral infections, certain bacterial infections, and chronic obstructive pulmonary disease. The small molecules may further be used to potentiate a diuretic effect of a diuretic compound. The small molecules may additionally be used to treat hypertension or thyroid conditions.

Growing community of inventors

San Francisco, CA, United States of America

Alan S Verkman